OCA at 08:21, 20 March 2024

OCA — Wed, 20 Mar 2024 08:21:11 GMT

←Older revision		Revision as of 08:21, 20 March 2024
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 8s0s is ~~ON HOLD~~	+	==A fragment-based inhibitor of SHP2==
-		+	<StructureSection load='8s0s' size='340' side='right'caption='[[8s0s]], [[Resolution\|resolution]] 1.94Å' scene=''>
-	~~Authors~~: ~~Cleasby~~, A., ~~Price~~, A.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[8s0s]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8S0S OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8S0S FirstGlance]. <br>
-	~~Description~~: ~~A fragment~~-~~based inhibitor~~ of ~~SHP2~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.94Å</td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1H4H:(1R,5S)-8-[7-(4-chloranyl-2-methyl-indazol-5-yl)-5H-pyrrolo[2,3-b]pyrazin-3-yl]-8-azabicyclo[3.2.1]octan-3-amine'>A1H4H</scene></td></tr>
-	[[Category: Cleasby, A]]	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8s0s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8s0s OCA], [https://pdbe.org/8s0s PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8s0s RCSB], [https://www.ebi.ac.uk/pdbsum/8s0s PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8s0s ProSAT]</span></td></tr>
-	[[Category: Price, A]]	+	</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/PTN11_HUMAN PTN11_HUMAN] Defects in PTPN11 are the cause of LEOPARD syndrome type 1 (LEOPARD1) [MIM:[https://omim.org/entry/151100 151100]. It is an autosomal dominant disorder allelic with Noonan syndrome. The acronym LEOPARD stands for lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and deafness.<ref>PMID:12058348</ref> <ref>PMID:14961557</ref> <ref>PMID:15389709</ref> <ref>PMID:15520399</ref> <ref>PMID:15121796</ref> <ref>PMID:15690106</ref> <ref>PMID:16679933</ref> Defects in PTPN11 are the cause of Noonan syndrome type 1 (NS1) [MIM:[https://omim.org/entry/163950 163950]. Noonan syndrome (NS) is a disorder characterized by dysmorphic facial features, short stature, hypertelorism, cardiac anomalies, deafness, motor delay, and a bleeding diathesis. Some patients with Noonan syndrome type 1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villomoduolar synovitis (PVNS) when occurring in the jaw or joints. Note=Mutations in PTPN11 account for more than 50% of the cases. Rarely, NS is associated with juvenile myelomonocytic leukemia (JMML). NS1 inheritance is autosomal dominant.<ref>PMID:11704759</ref> <ref>PMID:11992261</ref> <ref>PMID:12325025</ref> <ref>PMID:12161469</ref> <ref>PMID:12529711</ref> <ref>PMID:12634870</ref> <ref>PMID:12739139</ref> <ref>PMID:12960218</ref> <ref>PMID:12717436</ref> <ref>PMID:15384080</ref> <ref>PMID:15948193</ref> <ref>PMID:19020799</ref> Defects in PTPN11 are a cause of juvenile myelomonocytic leukemia (JMML) [MIM:[https://omim.org/entry/607785 607785]. JMML is a pediatric myelodysplastic syndrome that constitutes approximately 30% of childhood cases of myelodysplastic syndrome (MDS) and 2% of leukemia. It is characterized by leukocytosis with tissue infiltration and in vitro hypersensitivity of myeloid progenitors to granulocyte-macrophage colony stimulating factor.<ref>PMID:12717436</ref> Defects in PTPN11 are a cause of metachondromatosis (MC) [MIM:[https://omim.org/entry/156250 156250]. It is a skeletal disorder with radiologic fetarures of both multiple exostoses and Ollier disease, characterized by the presence of multiple enchondromas and osteochondroma-like lesions.<ref>PMID:20577567</ref>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/PTN11_HUMAN PTN11_HUMAN] Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 resulting in stimulatation of its RhoA binding activity.<ref>PMID:10655584</ref> <ref>PMID:18829466</ref> <ref>PMID:18559669</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Homo sapiens]]
		+	[[Category: Large Structures]]
		+	[[Category: Cleasby A]]
		+	[[Category: Price A]]

OCA at 08:03, 1 March 2024

OCA — Fri, 01 Mar 2024 08:03:17 GMT

←Older revision		Revision as of 08:03, 1 March 2024
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 8s0s is ON HOLD ~~until sometime in the future~~	+	The entry 8s0s is ON HOLD

	Authors: Cleasby, A., Price, A.		Authors: Cleasby, A., Price, A.

OCA: Protected "8s0s" [edit=sysop:move=sysop]

OCA — Wed, 21 Feb 2024 07:49:41 GMT

Protected "8s0s" [edit=sysop:move=sysop]

←Older revision

Revision as of 07:49, 21 February 2024

OCA: New page: '''Unreleased structure''' The entry 8s0s is ON HOLD until sometime in the future Authors: Cleasby, A., Price, A. Description: A fragment-based inhibitor of SHP2 [[Category: Unreleased...

OCA — Wed, 21 Feb 2024 07:49:40 GMT

New page: '''Unreleased structure''' The entry 8s0s is ON HOLD until sometime in the future Authors: Cleasby, A., Price, A. Description: A fragment-based inhibitor of SHP2 [[Category: Unreleased...

New page

'''Unreleased structure'''

The entry 8s0s is ON HOLD until sometime in the future

Authors: Cleasby, A., Price, A.

Description: A fragment-based inhibitor of SHP2
[[Category: Unreleased Structures]]
[[Category: Cleasby, A]]
[[Category: Price, A]]

8s0s - Revision history

OCA at 08:21, 20 March 2024

OCA at 08:03, 1 March 2024

OCA: Protected "8s0s" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 8s0s is ON HOLD until sometime in the future Authors: Cleasby, A., Price, A. Description: A fragment-based inhibitor of SHP2 [[Category: Unreleased...